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Incubation of big endothelin-1 (big ET-I,,,) with either the cytosolic or membrane fraction obtained from cultured endothelial cells, resulted in 
an increase in immunoreactive-endothelin @R-ET), which was markedly inhibited by metal chelators. Phosphoramidon, ametalloproteinase inhibi- 
tor, specifically suppressed the membrane fraction-induced increase in IR-ET, whereas the increase in IR-ET observed with the cytosolic fraction 
was not influenced by phosphoramidon. Reverse-phase (RP)-HPLC of the incubation mixture of big ET-1 with the cytosolic or membrane fraction 
revealed one major IR-ET component corresponding to the elution position of synthetic ET-l,,,. Simultaneously, immtmoreactivities like the C- 
terminal fragment (CTF,,,,) of big ET-l were present, as deduced from the RP-HPLC coupled with the radioimmunoassay for CTF. Our results 
indicate the presence of two types of metalloproteinases, which convert big ET-l to ET-l via a single cleavage between Trpti and VaP*, in vascular 
endothelial cells. 
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1. INTRODUCTION 
Endothelin-1 (ET-l) is a 21 amino acid peptide 
isolated from the culture medium of vascular en- 
dothelial cells (ECs) [ 11. From the structure of prepro- 
form deduced from the nucleotide sequence of cDNA 
encoding ET-l, Yanagisawa et al. [l] proposed a 
biosynthetic pathway of ET-l, i.e. the prepro-form is 
initially processed by dibasic pair specific proteolysis to 
produce a 39 amino acid intermediate form, termed big 
ET-l, and the big ET-1 is converted to the mature form 
by an unusual proteolytic processing between Trpzl and 
Valz2. Since the vasoconstrictor activity of big ET-1 is 
much lower than that of ET-1 [2,3], the conversion 
from big ET-l to ET-1 appears to be essential for the 
pathophysiological significance of ET-l. There is ac- 
cumulating evidence that the C-terminal ,fragment 
(CTF22-39) of big ET-l, as well as ET-1 and big ET-l, 
is present in the culture medium of ECs [4-61, hence 
ET-1 may be generated from big ET-l, via a single 
cleavage between Trp21 and Va122, by a putative big 
ET-l converting enzyme in ECs. 
Most recently, we found that ET-1 was generated via 
a single cleavage between Trp21 and Valz2 when in- 
cubating big ET-1 with the extract from cultured ECs at 
an acid pH [6]. Since the generation of ET-l was 
specifically inhibited by pepstatin-A, we suggested that 
an aspartic proteinase was involved in the conversion of 
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big ET-1 to ET-l in vascular ECs [7]. We have also 
noted that a relatively small increase in ET im- 
munoreactivity occurs during incubation of big ET-l 
with the cell extract at pH 7.0 [I. However, it remained 
to be determined whether this increase at the neutral pH 
was due to the conversion of big ET-l to ET-l. 
In the present study, we prepared both cytosolic and 
the membrane fractions from cultured ECs and in- 
vestigated whether these fractions possess converting 
activity at neutral pH. 
2. MATERIALS AND METHODS 
2.1. Cell culture and preparation of cytosolic and membrane 
fractions 
ECs isolated from fresh porcine thoracic aortas were cultured, as 
described [8]. To obtain cytosolic and membrane fractions of ECs, 
the confluent cells after 5-9 passages were scraped with a Cell Lifter 
(Costar, MA). After washing with phosphate buffered saline, the cells 
were homogenized in ice-cold 20 mM Tris-HCl buffer (pH 8.0) con- 
taining 30 mM KCl, then the preparation was centrifuged at 105008 
x g for 30 min. The resulting supematant was used as the cytosolic 
fraction. The pellet was washed with the Tris-HCI buffer and 
resuspended in the same buffer, then the preparation was used as the 
membrane fraction. 
2.2. Incubation of big ET-I with either cytosoiic or membrane 
fractions 
Fifty rd of each fraction (derived from 4 x 16 cells) and 0.05 ml 
of enzyme inhibitor cocktail were mixed with 0.35 ml of 50 mM 
sodium phosphate buffer @H 6.0-8.0). After preincubation at 37°C 
for 30 min, 0.05 ml of porcine big ET-l solution (final concentration: 
100 ng big ET-l/ml) was added to the mixture and the preparation 
was incubated at 37°C for 0.5-24 h. The reaction was stopped by boil- 
ing for 10 min. The samples were neutralimd (to pH 7.4) with diluted 
NaOH or HCI and centrifuged at 8000 x g for 5 min. The resulting 
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supernatant was diluted and served as sample for the radioim- 
munoassay (RIA) and reverse-phase (RP)-HPLC. Enzyme inhibitors 
used were bestatin (aminopeptidase inhibitor), E-64 (cysteine pro- 
teinase inhibitor), (p-amidinophenyl)metbanesulfonyl fluoride 
hydrochloride @-APMSF, serine proteinase inhibitor), chymostatin 
(chymotrypsin inhibitor), phosphoramidon (metalloproteinase in- 
hibitor) and thiorphan (neutral endopeptidase 24.11 inhibitor). Metal 
chelators, such as EDTA and l,lO-phenanthroline were also used. 
Thiorphan, EDTA and l,lO-phenanthroline were purchased from 
Sigma Chemical Co. (St. Louis, MO). pAPMSF was purchased from 
Wako Pure Chemical Industries Ltd. (Osaka, Japan). Other in- 
hibitors were obtained from Peptide Institute Inc. (Osaka, Japan). 
2.3. Radioimmunoassay (RIA) 
RIAs for ET and CTF were performed as described [6,7]. In RIA 
for ET, the cross-reactivity with big ET-l was lower than O.l%, 
whereas no cross-reactivity was observed with ET-l in RIA for CTF. 
The antiserum used in the latter had a 100% cross-reactivity with big 
ET-l. 
2.4. Reverse-phase high performance liquid chromatography 
(RP-HPLC) 
RP-HPLC was performed using a Capcell-Pak 5Crs-SG300 column 
(4.6 x 250 mm, Shiseido, Tokyo, Japan) eluted with a linear gradient 
from 0% to 35% CH;CN in 0.02% trifluoroacetic acid (TFA) for 15 
min. followed by isocratic elution at 35% CHsCN in 0.02% TFA for 
15 mhr and a linear gradient from 35% to 63% CHsCN in 0.02% TFA 
for 15 min. The flow rate was 0.5 ml/mm. Each fraction was 
evaporated and assayed for immunoreactive (IR)-ET and IR-CTF, us- 
ing RIA. 
2.5. Peptides 
Porcine ET-lr-21 and big ET-lr-r9 were obtained from Peptide In- 
stitute Inc. (Osaka, Japan). The CTIQ - 39 was prepared by solid 
phase synthesis. The homogeneity was confiied by RP-HPLC and 
amino acid analysis. 
3. RESULTS AND DISCUSSION 
We first examined the effects of enzyme inhibitors on 
increases in IR-ET content observed during incubation 
of big ET-1 with cytosolic or membrane fraction at pH 
7.0 for 6 h (Fig. 1). When big ET-l was incubated with 
the cytosolic fraction, the IR-ET content was markedly 
increased (0.23 f 0.02 to 4.81 + 0.35 ng IR-ET/ml), 
and no appreciable alteration was observed, in the 
presence or absence of enzyme inhibitors. Incubation 
with the membrane fraction also resulted in a marked 
increase in the IR-ET content (0.23 f 0.02 to 3.63 f 
0.32 ng IR-ET/ml), but the increased responses with 
this fraction were suppressed by the addition of enzyme 
inhibitors. When inhibitors were removed from the 
reaction system, one by one, it became evident that the 
removal of phosphoramidon, a metalloproteinase in- 
hibitor [9], greatly increased the IR-ET content in the 
reaction mixture. This suggested that a 
phosphoramidon-sensitive metalloproteinase par- 
ticipates in the increase in IR-ET. No ET- 
immunoreactivity was detected in cytosolic or mem- 
brane fraction. When ET-l, instead of big ET-l, was in- 
cubated under the same conditions with each fraction, 
the IR-ET was slightly decreased, but there were no 
noticeable differences in the presence or absence of en- 
zyme inhibitors, thereby suggesting that ET-1 was 
(ng IR-ET/ml) 
Fig. 1. Changes in IR-ET in the reaction mixture of big ET-l with 
either cytosolic or membrane fraction. Incubation was carried out at 
pH 7.0 for 6 h at 37”C, in tbe absence. or presence of enzyme in- 
hibitors (bestatin, lo-‘M; E-64, lo-‘M; chymostatin, 2 x 10V6 M; 
phosphoramidon, 10m5 M; pAPMSF, lo-’ M). Each column and 
bar represents the mean f SE from 6 separate xperiments. 
relatively stable during incubation at pH 7.0 for 6 h 
(data not shown). 
Fig. 2 shows the pH sensitivity (A) and the time- 
course (B) of the increase in IR-ET during incubation of 
big ET-l with cytosolic or membrane fraction. The op- 
timum pH of the former and the latter cases was 7.0 and 
6.5, respectively. In both cases, IR-ET increased linear- 
ly during 6 h after the start of incubation, and 
thereafter, the IR-ET content gradually decreased. 
Using RP-HPLC coupled with RIAs for the CTF and 
ET, we characterized the IR-CTF and IR-ET in the 
reaction mixture of big ET-1 with each fraction. The 
elution profiles in case of the cytosolic fraction revealed 
one major IR-ET component corresponding to the elu- 
tion position of synthetic ET-l (Fig. 3A), whereas IR- 
CTF consisted of one major and one minor component 
corresponding to elution positions of synthetic porcine 
big ET-l and CTF, respectively (Fig. 3B). Qualitatively 
similar results were obtained in case of the reaction mix- 
ture with the membrane fraction (Fig. 4A and B). The 
addition of phosphoramidon to the reaction mixture 
resulted in decreases in ET-l- and CTF-like materials 
accompanied by an increase in big ET-l-like materials 
(Fig. 4C and D). In all cases, the amounts of ET-l-like 
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Fig. 2. Effects of pH on the increase in IR-ET during incubation of big ET-l with either cytosolic or membrane fraction (A) and the time-course 
of the increased response (B). Incubation with the cytosolic fraction (0) was carried out in the absence of enzyme inhibitors. Incubation with the 
membrane fraction (*) was carried out in the presence of enzyme inhibitors, except for phosphor~idon. In experiments gaining the pH sensitivi- 
ty, the incubation was carried out for 6 h. The time-course was examined at pH 7.0. Each point and bar represents the mean + SE from 4 separate 
experiments. 
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Fig. 3. RP-HPLC profiles of IR-ET (A) and IR-CTF (B) in the reac- 
tion mixture of big ET-l with the cytosolic fraction. Incubation was 
carried out at pH 7.0 for 6 h in the absence of enzyme inhibitors. Ar- 
rows indicate the elution positions of ET-1 fl), CTF (2) and big ET-1 
(3). 
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materials almost equalled those of CTF-like materials, 
on a molar basis. These results strongly suggest hat the 
IR-ET observed by incubation of big ET-1 with either 
the cytosolic or membrane fraction is due to ET-l con- 
verted from big ET-l via a single cleavage between 
Trp” and Val**. In addition, we confirmed that 
phosphoramidon suppressed the membrane fraction- 
induced apparent conversion of big ET-l to ET-l. 
We examined effects of agents with the potential to 
inhibit the activity of metalloproteinase, on increases in 
IR-ET during incubation of big ET-l with each frac- 
tion. Phosphoramidon (lo- 7-10-4 M) suppressed 
dose-dependently the apparent converting activity of 
the membrane fraction, Metal chelators, such as EDTA 
and 1,l~phenanthroline (2 x 10q4 and 10e3 M), 
almost completely abolished the membrane fraction- 
induced apparent conversion (Fig. 5B). Thiorphan 
(10 - ‘- 10 - 5 M), a specific inhibitor of neutral endopep- 
tidase 24.11 [IO], an enzyme classified as a metallopro- 
teinase and widely ~stributed in the body in a 
membrane-bound and/or soluble form [I 11, had no 
suppressive action on the converting activity (Fig. 5B). 
Endopeptidase 24.11 has been reported to cleave pep- 
tides including enkephalins, kinins, atria1 natriuretic 
peptide and substance P [I 11. Since the concentrations 
of thiorphan we used are suf~cient o produce a com- 
plete inhibition of endopeptidase 24.11 activity [lo], the 
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Fig. 4. RP-HPLC profiles of IR-ET (A,C) and IR-CTF (B,D) in the reaction mixture of big ET-l with the membrane fraction. Incubation was 
carried out at pH 7.0 for 6 h in the absence (A,B) or presence (C,D) of 10e5 M phosphoramidon. Arrows indicate the elution positions of ET-l 
(l), CTF (2) and big ET-l (3). 
phosphoramidon-sensitive nzyme in the membrane fraction-induced apparent conversion. Thiorphan was 
fraction is presumably not endopeptidase 24.11. also without effect. However, two metal chelators 
In contrast to results seen with the membrane frac- potently inhibited the converting activity of this frac- 
tion, phosphoramidon had no effect on the cytosolic tion (Fig. 5A). Metal chelators inhibit both metallopro- 
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Fig. 5. Inhibitory effects of phosphoramidon (o), thiorphan (*), EDTA ( A ) and 1, IO-phenanthroline ( A ) on the increase in IR-ET during incuba- 
tion of big ET-l with either cytosolic (A) or membrane (B) fractions. Incubation was carried out at pH 7.0 for 6 h. Each point and bar represent 
the mean f SE from 4 separate xperiments. 
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teinases and metal-activated enzymes. The former en- 
zymes contain metal ions (usually zinc) at the active 
center, whereas the latter enzymes usually contain cys- 
teine or serine as the catalytic residues [121. According- 
ly, the metalloproteinases can often be distinguished 
from the metal-activated enzymes by the inhibition pro- 
file of enzyme inhibitors [12]. Taken together with our 
results (Fig. l), the conversion seen with the cytosolic 
fraction also seems to be mediated by enzymes belong- 
ing to met~loproteinases. 
The present study indicates that vascular ECs contain 
two types of metalloproteinases which convert big ET-l 
to ET-l via a single cleavage between Trp21 and Val”. 
One is phosphoramidon-sensitive and exists in a 
membrane-bound form, whereas the other is 
phosphoramidon-insensitive and may be present in a 
soluble form. Most recently, we found that ET-l can be 
generated by incubating big ET-l with the EC extract at 
an acid pH. Since the generation was specifically in- 
hibited by pepstatin-A, we considered that an aspartic 
proteinase may participate in the intra~ellul~ process- 
ing of big ET-1 in vascular ECs 171. Thus, the conver- 
sion of big ET-l in ECs is indeed complicated and may 
be mediated by more than one enzyme. We also obtain- 
ed data that the i.v. administration of phosphoramidon 
to anesthetized rats markedly suppressed the big 
ET-l-induced hypertensive ffect without affecting the 
hypertension induced by ET-I [13]. In addition, the 
secretion of ET-l from cultured ECs was abolished by 
the addition of phosphoramidon (Ikegawa et al., sub- 
mitted). From these findings, it seems reasonable to 
consider that phosphor~idon-sensitive metallopro- 
teinase which probably exists in a membr~e-bound 
form is the most plausible candidate for big ET-l con- 
verting enzyme, in vivo. 
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